A New Study Explores the Therapeutic Effect of Azilsartan and Niclosamide in Benign Prostatic Hyperplasia

The Department of Pharmacology at the College of Medicine, Al-Nahrain University, discussed the doctoral dissertation of student Ali Hussein Jasim, entitled:

This study aimed to investigate the potential protective effects of Azilsartan and Niclosamide in a testosterone-induced model of benign prostatic hyperplasia (BPH) by evaluating their impact on androgenic, inflammatory, fibrotic, anti-apoptotic, and proliferative markers. In addition, the study sought to assess their modulation of molecular targets, particularly Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in prostate tissues of rats.

These findings support the potential of Azilsartan and Niclosamide as novel therapeutic agents for managing BPH through modulation of key signaling pathways, including the androgen receptor axis, Wnt/β-catenin, TGFβ1/Smad2-3, NFκB, STAT3, and the renin-angiotensin system. The elevation of PPARγ indicates enhanced anti-inflammatory and anti-fibrotic activity.

The dissertation was successfully accepted with a grade of Excellent.

Division of Media and Government Communication
College of Medicine – Al-Nahrain University